# Bristol Myers Squibb

Breyanzi、Abecma — CD19 + BCMA.

Source: https://cn.bioecon.ru/companies/bristol-myers-squibb/
Updated: 2026-07-11

- 国家: United States
- 代码: BMY

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 2025年$482亿 | https://www.bms.com/investors/financial-reporting/key-facts.html, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm |
| 员工人数 | 约5,000名员工（细胞治疗业务）至34,100名（公司总计） | https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/ |
| 生产基地 | 马萨诸塞州Devens（细胞治疗） | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| 生产基地 | 华盛顿州Bothell；新泽西州Summit；新泽西州Warren（细胞治疗） | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| 生产基地 | 荷兰莱顿（细胞治疗，在建/已完成） | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| 监管批准 | Breyanzi监测/活性更新于2026年6月在加拿大获批；Breyanzi与Abecma的美国说明书更新于2025年6月 | https://investors.bms.com/iframes/press-releases/press-release-details/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx, https://news.bms.com/news/corporate-financial/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx, https://www.bms.com/assets/bms/ca/documents/productmonograph/BREYANZI_EN_PM.pdf, https://www.bms.com/ca/en/media/press-release-listing/2026-06-17-press-release.html, https://www.hematologyadvisor.com/news/fda-removes-rems-reduces-monitoring-requirements-for-breyanzi-and-abecma/ |
| 产能 | 通过新建基地（Devens、Leiden）及创新制造方案实现扩张 [中等置信度] | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |

独立来源: bms.com, contractpharma.com, fiercepharma.com, hematologyadvisor.com, investors.bms.com, news.bms.com, sec.gov

## 技术

- [CAR-T 细胞疗法](https://cn.bioecon.ru/technology/car-t-cell-therapy/)
- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)